<DOC>
	<DOCNO>NCT00405236</DOCNO>
	<brief_summary>Patients COPD experience exacerbation major cause morbidity . Exacerbations associate increased airway systemic inflammation experience frequent exacerbation demonstrate increase inflammation stable state . Tiotropium show reduce exacerbation frequency might postulate due reduction inflammation . The study compare airway inflammation exacerbation frequency patient COPD tiotropium placebo .</brief_summary>
	<brief_title>Effect Tiotropium Inflammation Exacerbations COPD</brief_title>
	<detailed_description>Patients COPD randomise tiotropium placebo addition usual medication . They follow prospectively 1 year provide sputum quantification IL-6 IL-8 baseline 3 monthly intervals.Serum IL-6 also quantify baseline year . Changes inflammatory marker assess analysis area curve log transform data . Exacerbation frequency calculate patient diary card use previously validate symptom-based exacerbation definition .</detailed_description>
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Tiotropium Bromide</mesh_term>
	<criteria>diagnosis COPD , FEV1 &lt; 80 % predict , minimum 10 pack year smoke history asthma , atopic disease , eosinophilia , history malignancy , history clinically significant pulmonary disease</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2006</verification_date>
	<keyword>inflammation</keyword>
	<keyword>exacerbation</keyword>
</DOC>